Cover Image
Market Research Report

Global Needle Free Drug Delivery Market Outlook 2020

Published by RNCOS E-Services Pvt. Ltd. Product code 330510
Published Content info 80 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Needle Free Drug Delivery Market Outlook 2020
Published: May 1, 2015 Content info: 80 Pages
Description

The needle-free drug delivery technology is an innovative technique to deliver drugs into a person's body without piercing the skin. The global needle-free drug delivery industry has been riding the tidal waves for the past few years, growing swiftly and presenting ample opportunities to the industry's players. With favorable demographics, positive eco-financial dynamics, and rising awareness, the global needle-free drug delivery market is poised to scale newer acmes. Moreover, augmented M&A activity in the industry, introduction of novel needle-free drug delivery devices, like micro needles, patch and roller, and entry of new players are set to further boost the market's growth.

The latest research by RNCOS titled, "Global Needle Free Drug Delivery Market Outlook 2020", unfolds the market dynamics of the needle-free drug delivery market. In this report, the global needle-free drug delivery industry has been split into five distinct segments viz.: Jet injectors, Transdermal Patches, Micro Needles, and Oral and Inhalation drug delivery, with their current and future outlook to 2020 depicted. The transdermal patches and inhalation drug delivery system markets are further divided into sub-segments, with each segment scrutinized in detail. The report identifies and highlights the segments that offer the maximum opportunity for growth in the global market.

Our industry analysts studied all the facets of the global needle-free drug delivery market to portray a crystal clear picture of the current as well as expected future market outlook. Major drivers and trends have been identified that will act as catalysts towards boosting the industry's growth along with roadblocks hindering the market's growth. The study also delves into the regulatory environment affecting the needle-free drug delivery devices in a number of countries.

It further highlights the competitive landscape of the global needle-free drug delivery market, describing the business, financials, strengths and weaknesses, and recent developments of major industry players, thus helping the reader to gain a crucial insight into the key market players' performances and strategies for growth. Holistically, the research provides all the prerequisite information for clients looking to make a debut in this industry and facilitates them to formulate schemes while going for an investment/partnership in the global needle-free drug delivery industry.

Table of Contents

Table of Contents

1. Analyst View

2. Research Methodology

3. Drivers

  • 3.1 Increasing Incidence of Chronic Diseases
  • 3.2 Increased Affordability
  • 3.3 Benefits over Conventional Drug Delivery Devices
  • 3.4 Expansion in Emerging Markets

4. Challenges

  • 4.1 High Prices
  • 4.2 Testing and Regulatory Issues
  • 4.3 Low Awareness

5. Regulatory Landscape

  • 5.1 US
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China
  • 5.5 India

6. Needle Free Drug Delivery Market Outlook to 2020

  • 6.1 Current Market size and Future Outlook

7. Market Segmentation

  • 7.1 By Technology
    • 7.1.1 Oral Drug Delivery System
    • 7.1.2 Inhaler Drug Delivery System
    • 7.1.3 Transdermal Drug Delivery System
    • 7.1.4 Jet injector Drug Delivery System
    • 7.1.5 Micro Needle Drug Delivery System
  • 7.2 By Application
  • 7.3 By geography

8. Industry Trends

  • 8.1 Introduction of Low Cost Inhalers for Developing Countries
  • 8.2 Innovation in Advanced Dry Powder Inhalers
  • 8.3 Oral Drug Delivery System goes Electrical
  • 8.4 Consolidation in the Market

9. Competitor Profiles

  • 9.1 Mylan Inc.
  • 9.2 3M (MMM)
  • 9.3 Novatis
  • 9.4 AstraZeneca Plc
  • 9.5 Antares Pharma, Inc.
  • 9.6 GlaxoSmithKline Plc (GSK)
  • 9.7 Sanofi
  • 9.8 Boehringer Ingelheim GmbH
  • 9.9 Merck & Co.

List of Figures:

  • Figure 6-1: Global - Needle Free Drug Delivery Market (Billion US$), 2014-2020
  • Figure 7-1: Global - Needle Free Drug Delivery Market by Technology (%), 2014
  • Figure 7-2: Global - Oral Drug Delivery Market (Billion US$), 2014-2020
  • Figure 7-3: Global - Inhaler Drug Delivery Market (Billion US$), 2014-2020
  • Figure 7-4: Global - Inhaler Drug Delivery Market by Segment (%), 2014
  • Figure 7-5: Global - Inhaled Drug Delivery Market by Players (%), 2013
  • Figure 7-6: Global - Transdermal Drug Delivery Market (Billion US$), 2014-2020
  • Figure 7-7: Global - Transdermal Drug Delivery Market by Sub-Segment (%), 2013
  • Figure 7-8: Global - Jet Injectors Market (Million US$), 2014-2020
  • Figure 7-9: Global - Jet Injectors Market by Players (%), 2014
  • Figure 7-10: Global - Needle Free Drug Delivery Market by Application (%), 2014
  • Figure 7-11: Global - Needle Free Drug Delivery Market by Region (%), 2014
  • Figure 9-1: Mylan - Breakup of Revenue by Geography (%), 2014
  • Figure 9-2: 3M - Breakup of Revenue by Geography (%), 2014
  • Figure 9-3: Novartis - Breakup of Revenue by Geography (%), 2014
  • Figure 9-4: AstraZeneca Plc - Breakup of Revenue by Geography (%), 2014
  • Figure 9-5: Antares Pharma Inc. - Breakup of Revenue by Geography (%), 2014
  • Figure 9-6: GlaxoSmithKline Plc - Breakup of Revenue by Geography (%), 2014
  • Figure 9-7: Sanofi - Breakup of Revenue by Geography (%), 2014
  • Figure 9-8: Boehringer Ingelheim GmbH - Breakup of Revenue by Geography (%), 2013
  • Figure 9-9: Merck & Co - Breakup of Revenue by Geography (%), 2014

List of Tables:

  • Table 7-1: Oral Drug Delivery - Pipeline Analysis (2014)
  • Table 7-2: Inhaled Drug Delivery - Pipeline Analysis (2014)
  • Table 7-3: Transdermal Drug Delivery - Pipeline Analysis (2014)
  • Table 7-4: Jet Injectors Drug Delivery - Pipeline Analysis (2014)
  • Table 7-5: Micro Needles Drug Delivery - Pipeline Analysis (2014)
  • Table 8-1: Recent M&A in the Needle Free Drug Delivery Industry (2014)
  • Table 9-1: Mylan - Key Financials (Million US$), 2012-2014
  • Table 9-2: Mylan - Strengths and Weaknesses
  • Table 9-3: 3M - Key Financials (Million US$), 2012-2014
  • Table 9-4: 3M - Strengths and Weaknesses
  • Table 9-5: Novartis - Key Financials (Million US$), 2012-2014
  • Table 9-6: Novartis - Strengths and Weaknesses
  • Table 9-7: AstraZeneca Plc - Key Financials (Million US$), 2012-2014
  • Table 9-8: Astrazeneca - Strengths and Weaknesses
  • Table 9-9: Antares Pharma Inc. - Key Financials (Million US$), 2012-2014
  • Table 9-10: GlaxoSmithKline Plc - Key Financials (Million US$), 2012-2014
  • Table 9-11: GlaxoSmithKline - Strengths and Weaknesses
  • Table 9-12: Sanofi - Key Financials (Million US$), 2012-2014
  • Table 9-13: Sanofi - Strengths and Weaknesses
  • Table 9-14: Boehringer Ingelheim GmbH- Key Financials, (Million US$), 2011-2013
  • Table 9-15: Boehringer Ingelheim GmbH - Strengths and Weaknesses
  • Table 9-16: Merck & Co- Key Financials (Million US$), 2012-2014
  • Table 9-17: Merck & Co- Strengths and Weaknesses
Back to Top